Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia.
Adnan Awad S, Dufva O, Klievink J, Karjalainen E, Ianevski A, Pietarinen P, Kim D, Potdar S, Wolf M, Lotfi K, Aittokallio T, Wennerberg K, Porkka K, Mustjoki S. Adnan Awad S, et al. Among authors: potdar s. Cell Rep Med. 2024 May 21;5(5):101521. doi: 10.1016/j.xcrm.2024.101521. Epub 2024 Apr 22. Cell Rep Med. 2024. PMID: 38653245 Free article.
Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO, Eide CA, Ayuda-Durán P, Potdar S, Kuusanmäki H, Andersson EI, Mpindi JP, Pemovska T, Kontro M, Heckman CA, Kallioniemi O, Wennerberg K, Hjorth-Hansen H, Druker BJ, Enserink JM, Tyner JW, Mustjoki S, Porkka K. Pietarinen PO, et al. Among authors: potdar s. Oncotarget. 2017 Apr 4;8(14):22606-22615. doi: 10.18632/oncotarget.15146. Oncotarget. 2017. PMID: 28186983 Free PMC article.
Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia.
Malani D, Kumar A, Brück O, Kontro M, Yadav B, Hellesøy M, Kuusanmäki H, Dufva O, Kankainen M, Eldfors S, Potdar S, Saarela J, Turunen L, Parsons A, Västrik I, Kivinen K, Saarela J, Räty R, Lehto M, Wolf M, Gjertsen BT, Mustjoki S, Aittokallio T, Wennerberg K, Heckman CA, Kallioniemi O, Porkka K. Malani D, et al. Among authors: potdar s. Cancer Discov. 2022 Feb;12(2):388-401. doi: 10.1158/2159-8290.CD-21-0410. Epub 2021 Nov 17. Cancer Discov. 2022. PMID: 34789538 Free PMC article.
KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia.
Malani D, Yadav B, Kumar A, Potdar S, Kontro M, Kankainen M, Javarappa KK, Porkka K, Wolf M, Aittokallio T, Wennerberg K, Heckman CA, Murumägi A, Kallioniemi O. Malani D, et al. Among authors: potdar s. Leukemia. 2020 Oct;34(10):2780-2784. doi: 10.1038/s41375-020-0978-7. Epub 2020 Jul 17. Leukemia. 2020. PMID: 32678289 No abstract available.
Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia.
White BS, Khan SA, Mason MJ, Ammad-Ud-Din M, Potdar S, Malani D, Kuusanmäki H, Druker BJ, Heckman C, Kallioniemi O, Kurtz SE, Porkka K, Tognon CE, Tyner JW, Aittokallio T, Wennerberg K, Guinney J. White BS, et al. Among authors: potdar s. NPJ Precis Oncol. 2021 Jul 23;5(1):71. doi: 10.1038/s41698-021-00209-9. NPJ Precis Oncol. 2021. PMID: 34302041 Free PMC article.
Prediction of drug combination effects with a minimal set of experiments.
Ianevski A, Giri AK, Gautam P, Kononov A, Potdar S, Saarela J, Wennerberg K, Aittokallio T. Ianevski A, et al. Among authors: potdar s. Nat Mach Intell. 2019 Dec;1(12):568-577. doi: 10.1038/s42256-019-0122-4. Epub 2019 Dec 9. Nat Mach Intell. 2019. PMID: 32368721 Free PMC article.
101 results